- Beta Blockers
- ACE Inhibitors
- Diuretics
- Anticoagulants
Takotsubo Cardiomyopathy Treatment Market size was valued at USD 1,823.4 million in 2023. and is anticipated to grow to USD 2,548.7 million by 2030, and is poised to grow at a 4.6% CAGR from 2024 to 2030. Takotsubo Cardiomyopathy is a temporary heart condition that develops in response to an intense emotional and physical syndrome, also known as stress cardiomyopathy or broken heart syndrome. It occurs due to the weakening of the heart muscle and feels like a heart attack. In this condition, the main pumping changes its shape and affects the ability of the heart to pump.Government initiatives promoting awareness, increased diagnosis rate, and efficient treatment options boost market growth.
Pharmaceutical companies involved in research and development activities towards tokotsubo cardiomyopathy treatment are expected to create lucrative opportunities in the market. The high cost of medication and complications associated with the treatment, such as hypertension and heart attack, hampers the market growth and become a major restraint in the expansion of treatment therapies. According to the British Heart Foundation, 7.6 million people in the United Kingdom had heart and circulatory diseases by March 2021, which amounted to 27% deaths, with approximately 43,000 people dying before the age of 75. Region-wise, North America held the major market share in 2022 and is expected to dominate the global Takotsubo Cardiomyopathy Treatment Market in the forecasted years.
Takotsubo Cardiomyopathy Treatment Market Key Developments:
According to the National Institutes of Health, the prevalence of TS has been reported to be approximately 2% (up to 10% if only women are considered) of all patients presenting with clinical manifestations of ACS.
Takotsubo Cardiomyopathy Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
4.6%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Takotsubo Cardiomyopathy Treatment Market Dynamics
The increase in the prevalence of vascular diseases worldwide is the primary market driver in the Takotsubo Cardiomyopathy Treatment Market during the forecast period. The changes in lifestyle and increasing prevalence of stress, anxiety, and depression across the world enhanced cardiovascular patient counts, driving the cardiac MRI diagnostics industry. In addition, government initiatives for the prevention of cardiovascular diseases and pharmaceutical key players focusing on developing novel drugs are the primary factor that drives the market at a significant rate.
Asia-Pacific Got Significant Share
Takotsubo Cardiomyopathy Treatment Market Regional Analysis
The Takotsubo Cardiomyopathy Treatment Market in the Asia Pacific holds significant market shares in 2022 due to increasing cardiomyopathy in the geriatric population. Over the forecast period, it is predicted to grow rapidly due to the lower cost of drugs, the increase in diagnosis rates, and the healthcare infrastructure. North America holds a significant market share in the global market and dominates the global market; increasing incidence of heart disorder in the region, with continuous technological development and rising healthcare awareness, are the major factors for market growth, and it is expected to endure dominance in the upcoming years due to presence of global key players in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The takotsubo cardiomyopathy treatment market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Takotsubo Cardiomyopathy Treatment Market Segmentation
By Treatment
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The takotsubo cardiomyopathy treatment market size was valued at usd 1,823.4 million in 2022 and is anticipated to grow usd 2,548.7 million by 2023
The leading players in the takotsubo cardiomyopathy treatment market are AbbVie, Alembic Pharmaceuticals Limited, Zydus Cadila, Amneal Pharmaceuticals LLC, Aspen Holdings, Bristol Myers Squibb Company, Eisai Co., Ltd., Pierre Fabre Group, ANI Pharmaceuticals, Inc., Mylan N.V., Novartis AG, Lupin, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.,
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast presented from 2023 – 2029.
| 1.Executive Summary |
| 2.Global Takotsubo Cardiomyopathy Treatment Market Introduction |
| 2.1.Global Takotsubo Cardiomyopathy Treatment Market - Taxonomy |
| 2.2.Global Takotsubo Cardiomyopathy Treatment Market - Definitions |
| 2.2.1.Treatment |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3.Global Takotsubo Cardiomyopathy Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Takotsubo Cardiomyopathy Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Takotsubo Cardiomyopathy Treatment Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Beta Blockers |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. ACE Inhibitors |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Diuretics |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Anticoagulants |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Takotsubo Cardiomyopathy Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Hospital Pharmacy |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacy |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online Pharmacy |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Takotsubo Cardiomyopathy Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Takotsubo Cardiomyopathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Beta Blockers |
| 8.1.2.ACE Inhibitors |
| 8.1.3.Diuretics |
| 8.1.4.Anticoagulants |
| 8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacy |
| 8.2.2.Retail Pharmacy |
| 8.2.3.Online Pharmacy |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Takotsubo Cardiomyopathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Beta Blockers |
| 9.1.2.ACE Inhibitors |
| 9.1.3.Diuretics |
| 9.1.4.Anticoagulants |
| 9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacy |
| 9.2.2.Retail Pharmacy |
| 9.2.3.Online Pharmacy |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Takotsubo Cardiomyopathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Beta Blockers |
| 10.1.2.ACE Inhibitors |
| 10.1.3.Diuretics |
| 10.1.4.Anticoagulants |
| 10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacy |
| 10.2.2.Retail Pharmacy |
| 10.2.3.Online Pharmacy |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Takotsubo Cardiomyopathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Beta Blockers |
| 11.1.2.ACE Inhibitors |
| 11.1.3.Diuretics |
| 11.1.4.Anticoagulants |
| 11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacy |
| 11.2.2.Retail Pharmacy |
| 11.2.3.Online Pharmacy |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Takotsubo Cardiomyopathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Beta Blockers |
| 12.1.2.ACE Inhibitors |
| 12.1.3.Diuretics |
| 12.1.4.Anticoagulants |
| 12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacy |
| 12.2.2.Retail Pharmacy |
| 12.2.3.Online Pharmacy |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.AbbVie |
| 13.2.2.Aspen Holdings |
| 13.2.3.Bristol Myers Squibb Company |
| 13.2.4.Eisai Co., Ltd. |
| 13.2.5.Pierre Fabre Group |
| 13.2.6.ANI Pharmaceuticals, Inc. |
| 13.2.7.Mylan N.V. |
| 13.2.8.Novartis AG, |
| 13.2.9.GlaxoSmithKline plc |
| 13.2.10.Sun Pharmaceutical Industries Ltd. |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- AbbVie
- Aspen Holdings
- Bristol Myers Squibb Company
- Eisai Co., Ltd.
- Pierre Fabre Group
- ANI Pharmaceuticals, Inc.
- Mylan N.V.
- Novartis AG,
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.